Local termination of 3′-5′-cyclic adenosine monophosphate signals: The role of a kinase anchoring protein-tethered phosphodiesterases

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 4, 2011, Pages 345-353

  Stangherlin, Alessandra ^a   Zaccolo, Manuela ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

AKAP; cAMP; compartmentalization; heart; PDE; PKA; signaling

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; MEMBRANE PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 7; MUSCLE SPECIFIC A KINASE ANCHORING PROTEIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE 4D3; PHOSPHODIESTERASE IV; UNCLASSIFIED DRUG; YOTIAO PROTEIN;

AMINO TERMINAL SEQUENCE; BETA ADRENERGIC STIMULATION; CARDIOVASCULAR SYSTEM; CELLULAR DISTRIBUTION; ENZYME MECHANISM; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HORMONAL REGULATION; HUMAN; MOLECULAR DYNAMICS; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SARCOPLASMIC RETICULUM; SERTOLI CELL; SIGNAL TRANSDUCTION;

A KINASE ANCHOR PROTEINS; ANIMALS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HEART; HUMANS; PHOSPHORIC DIESTER HYDROLASES; SIGNAL TRANSDUCTION;

EID: 80053974395     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182214f2b     Document Type: Review

References (139)

1. Sutherland EW, Robison GA. The role of cyclic-3′,5′-AMP in responses to catecholamines and other hormones. Pharmacol Rev. 1966;18: 145-161.
2. Walsh DA, Perkins JP, Krebs EG. An adenosine 3′,5′- monophosphatedependant protein kinase from rabbit skeletal muscle. J Biol Chem. 1968;243:3763-3765.
3. Erlichman J, Hirsch AH, Rosen OM. Interconversion of cyclic nucleotide-activated and cyclic nucleotide-independent forms of a protein kinase from beef heart. Proc Natl Acad Sci U S A. 1971;68:731-735.
4. Rubin CS, Erlichman J, Rosen OM. Cyclic adenosine 3′,5′- monophosphate- dependent protein kinase of human erythrocyte membranes. J Biol Chem. 1972;247:6135-6139.
5. Rubin CS, Erlichman J, Rosen OM. Molecular forms and subunit composition of a cyclic adenosine 3′,5′-monophosphate-dependent protein kinase purified from bovine heart muscle. J Biol Chem. 1972; 247:36-44.
6. Rosen OM, Erlichman J, Rubin CS. Molecular structure and characterization of bovine heart protein kinase. Adv Cyclic Nucleotide Res. 1975;5:253-263.
7. Kuo JF, Greengard P. An adenosine 3′,5′-monophosphate- dependent protein kinase from Escherichia coli. J Biol Chem. 1969;244:3417-3419.
8. Corbin JD, Keely SL, Park CR. The distribution and dissociation of cyclic adenosine 3′:5′-monophosphate-dependent protein kinases in adipose, cardiac, and other tissues. J Biol Chem. 1975;250:218-225.
9. Hofmann F, Beavo JA, Bechtel PJ, et al. Comparison of adenosine 3′:5′- monophosphate-dependent protein kinases from rabbit skeletal and bovine heart muscle. J Biol Chem. 1975;250:7795-7801.
10. Greengard P. Phosphorylated proteins as physiological effectors. Science. 1978;199:146-152.
11. Corbin JD, Sugden PH, Lincoln TM, et al. Compartmentalization of adenosine 3′:5′-monophosphate and adenosine 3′:5′- monophosphate-dependent protein kinase in heart tissue. J Biol Chem. 1977;252:3854-3861. (Pubitemid 8127237)
12. Brunton LL, Hayes JS, Mayer SE. Hormonally specific phosphorylation of cardiac troponin I and activation of glycogen phosphorylase. Nature. 1979;280:78-80. (Pubitemid 9221184)
13. Buxton IL, Brunton LL. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J Biol Chem. 1983;258: 10233-10239. (Pubitemid 14241179)
14. Hayes JS, Brunton LL, Brown JH, et al. Hormonally specific expression of cardiac protein kinase activity. Proc Natl Acad Sci U S A. 1979;76: 1570-1574. (Pubitemid 9175360)
15. Keely SL. Activation of cAMP-dependent protein kinase without a corresponding increase in phosphorylase activity. Res Commun Chem Pathol Pharmacol. 1977;18:283-290. (Pubitemid 8203511)
16. 2+ transients. Circ Res. 1991;69:1369-1379.
17. Kuschel M, Zhou YY, Cheng H, et al. G(i) protein-mediated functional compartmentalization of cardiac beta(2)-adrenergic signaling. J Biol Chem. 1999;274:22048-22052.
18. 2+ dynamics, contractility, or phospholamban phosphorylation. J Biol Chem. 1994;269:19151-19156.
19. Vila Petroff MG, Egan JM, Wang X, et al. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res. 2001;89:445-452. (Pubitemid 34132661)
20. 2+ channels by beta-adrenergic agonists. Proc Natl Acad Sci U S A. 1996;93:295-299.
21. Rochais F, Abi-Gerges A, Horner K, et al. A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gscoupled receptors in adult rat ventricular myocytes. Circ Res. 2006;98: 1081-1088.
22. Zaccolo M, De Giorgi F, Cho CY, et al. A genetically encoded, fluorescent indicator for cyclic AMP in living cells. Nat Cell Biol. 2000; 2:25-29.
23. Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science. 2002;295: 1711-1715. (Pubitemid 34202906)
24. Hayes JS, Brunton LL. Functional compartments in cyclic nucleotide action. J Cyclic Nucleotide Res. 1982;8:1-16. (Pubitemid 12047342)
25. Lohmann SM, Walter U. Regulation of the cellular and subcellular concentrations and distribution of cyclic nucleotide-dependent protein kinases. Adv Cyclic Nucleotide Protein Phosphorylation Res. 1984;18: 63-117.
26. Carr DW, Hausken ZE, Fraser ID, et al. Association of the type II cAMPdependent protein kinase with a human thyroid RII-anchoring protein. Cloning and characterization of the RII-binding domain. J Biol Chem. 1992;267:13376-13382.
27. Pidoux G, Tasken K. Specificity and spatial dynamics of protein kinase A signaling organized by A-kinase-anchoring proteins. J Mol Endocrinol. 2010;44:271-284.
28. Newlon MG, Roy M, Morikis D, et al. The molecular basis for protein kinase A anchoring revealed by solution NMR. Nat Struct Biol. 1999;6: 222-227. (Pubitemid 29107224)
29. Gold MG, Lygren B, Dokurno P, et al. Molecular basis of AKAP specificity for PKA regulatory subunits. Mol Cell. 2006;24:383-395. (Pubitemid 44647900)
30. Kinderman FS, Kim C, von Daake S, et al. A dynamic mechanism for AKAP binding to RII isoforms of cAMP-dependent protein kinase. Mol Cell. 2006;24:397-408. (Pubitemid 44647908)
31. Bregman DB, Bhattacharyya N, Rubin CS. High affinity binding protein for the regulatory subunit of cAMP-dependent protein kinase II-B. Cloning, characterization, and expression of cDNAs for rat brain P150. J Biol Chem. 1989;264:4648-4656. (Pubitemid 19081372)
32. Kapiloff MS, Schillace RV, Westphal AM, et al. mAKAP: an A-kinase anchoring protein targeted to the nuclear membrane of differentiated myocytes. J Cell Sci. 1999;112(pt 16):2725-2736. (Pubitemid 29429795)
33. Fraser ID, Tavalin SJ, Lester LB, et al. A novel lipid-anchored A-kinase anchoring protein facilitates cAMP-responsive membrane events. EMBO J. 1998;17:2261-2272. (Pubitemid 28171911)
34. Westphal RS, Tavalin SJ, Lin JW, et al. Regulation of NMDA receptors by an associated phosphatase-kinase signaling complex. Science. 1999; 285:93-96. (Pubitemid 29307572)
35. Algrain M, Turunen O, Vaheri A, et al. Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membrane-cytoskeletal linker. J Cell Biol. 1993;120:129-139.
36. Lim CJ, Han J, Yousefi N, et al. Alpha4 integrins are type I cAMPdependent protein kinase-anchoring proteins. Nat Cell Biol. 2007;9: 415-421. (Pubitemid 46511074)
37. Kovanich D, van der Heyden MA, Aye TT, et al. Sphingosine kinase interacting protein is an A-kinase anchoring protein specific for type I cAMP-dependent protein kinase. Chembiochem. 2010;11:963-971.
38. Huang LJ, Durick K, Weiner JA, et al. Identification of a novel protein kinase A anchoring protein that binds both type I and type II regulatory subunits. J Biol Chem. 1997;272:8057-8064. (Pubitemid 27137372)
39. Wang L, Sunahara RK, Krumins A, et al. Cloning and mitochondrial localization of full-length D-AKAP2, a protein kinase A anchoring protein. Proc Natl Acad Sci U S A. 2001;98:3220-3225. (Pubitemid 32220826)
40. Lissandron V, Zaccolo M. Compartmentalized cAMP/PKA signalling regulates cardiac excitation-contraction coupling. J Muscle Res Cell Motil. 2006;27:399-403. (Pubitemid 44325618)
41. Scott JD, Santana LF. A-kinase anchoring proteins: getting to the heart of the matter. Circulation. 2010;121:1264-1271.
42. Sumandea CA, Garcia-Cazarin ML, Bozio CH, et al. Cardiac troponin T, a sarcomeric AKAP, tethers protein kinase A at the myofilaments. J Biol Chem. 2011;286:530-541.
43. Fink MA, Zakhary DR, Mackey JA, et al. AKAP-mediated targeting of protein kinase a regulates contractility in cardiac myocytes. Circ Res. 2001;88:291-297. (Pubitemid 32173752)
44. Diviani D. Modulation of cardiac function by A-kinase anchoring proteins. Curr Opin Pharmacol. 2008;8:166-173.
45. Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000;101:365-376.
46. Gray PC, Johnson BD, Westenbroek RE, et al. Primary structure and function of an A kinase anchoring protein associated with calcium channels. Neuron. 1998;20:1017-1026. (Pubitemid 28247406)
47. 2+ re-uptake into heart sarcoplasmic reticulum. EMBO Rep. 2007;8: 1061-1067. (Pubitemid 350042342)
48. Gardner LA, Tavalin SJ, Goehring AS, et al. AKAP79-mediated targeting of the cyclic AMP-dependent protein kinase to the beta1- adrenergic receptor promotes recycling and functional resensitization of the receptor. J Biol Chem. 2006;281:33537-33553. (Pubitemid 46036735)
49. Malbon CC, Tao J,Wang HY. AKAPs (A-kinase anchoring proteins) and molecules that compose their G-protein-coupled receptor signalling complexes. Biochem J. 2004;379:1-9. (Pubitemid 38491353)
50. Tao J, Wang HY, Malbon CC. Src docks to A-kinase anchoring protein gravin, regulating beta2-adrenergic receptor resensitization and recycling. J Biol Chem. 2007;282:6597-6608. (Pubitemid 47100888)
51. Shih M, Lin F, Scott JD, et al. Dynamic complexes of beta2-adrenergic receptors with protein kinases and phosphatases and the role of gravin. J Biol Chem. 1999;274:1588-1595.
52. Hayabuchi Y, Dart C, Standen NB. Evidence for involvement of Akinase anchoring protein in activation of rat arterial K(ATP) channels by protein kinase A. J Physiol. 2001;536:421-427. (Pubitemid 32976123)
53. Zhong J, Hume JR, Keef KD. Anchoring protein is required for cAMPdependent stimulation of L-type Ca(2+) channels in rabbit portal vein. Am J Physiol. 1999;277:C840-C844. (Pubitemid 29525923)
54. Lester LB, Langeberg LK, Scott JD. Anchoring of protein kinase A facilitates hormone-mediated insulin secretion. Proc Natl Acad Sci U S A. 1997;94:14942-14947. (Pubitemid 28041479)
55. Dodge KL, Carr DW, Yue C, et al. A role for AKAP (A kinase anchoring protein) scaffolding in the loss of a cyclic adenosine 3′,5′- monophosphate inhibitory response in late pregnant rat myometrium. Mol Endocrinol. 1999;13:1977-1987. (Pubitemid 30637260)
56. Snyder EM, Colledge M, Crozier RA, et al. Role for A kinase-anchoring proteins (AKAPS) in glutamate receptor trafficking and long term synaptic depression. J Biol Chem. 2005;280:16962-16968. (Pubitemid 41389157)
57. Sutherland EW, Rall TW. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J Biol Chem. 1958; 232:1077-1091.
58. Butcher RW, Sutherland EW. Adenosine 3′,5′-phosphate in biological materials. I. Purification and properties of cyclic 3′,5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′,5′-phosphate in human urine. J Biol Chem. 1962;237:1244-1250.
59. Kakiuchi S, Yamazaki R. Calcium dependent phosphodiesterase activity and its activating factor (PAF) from brain studies on cyclic 3′,5′- nucleotide phosphodiesterase (3). Biochem Biophys Res Commun. 1970; 41:1104-1110.
60. Beavo JA, Hardman JG, Sutherland EW. Stimulation of adenosine 3′,5′- monophosphate hydrolysis by guanosine 3′,5′- monophosphate. J Biol Chem. 1971;246:3841-3846.
61. Thompson WJ, Appleman MM. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry. 1971;10:311-316.
62. Beavo JA, Hansen RS, Harrison SA, et al. Identification and properties of cyclic nucleotide phosphodiesterases. Mol Cell Endocrinol. 1982;28: 387-410. (Pubitemid 13253569)
63. Levin RM, Weiss B. Mechanism by which psychotropic drugs inhibit adenosine cyclic 3′,5′-monophosphate phosphodiesterase of brain. Mol Pharmacol. 1976;12:581-589.
64. Wells JN, Garst JE, Kramer GL. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from pig coronary arteries by 1,3- disubstituted and 1,3,8-trisubstituted xanthines. J Med Chem. 1981; 24:954-958. (Pubitemid 11015163)
65. Wood MA, Hess ML. Long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors. Am J Med Sci. 1989;297:105-113. (Pubitemid 19071022)
66. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006;109:366-398. (Pubitemid 43132818)
67. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481-511.
68. 2+/CaM-activated phosphodiesterases: expression and physiological functions. Adv Second Messenger Phosphoprotein Res. 1997;31: 237-251.
69. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J. 2003;370:1-18. (Pubitemid 36259414)
70. McCahill AC, Huston E, Li X, et al. PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases. Handb Exp Pharmacol. 2008:125-166.
71. Yang Q, Paskind M, Bolger G, et al. A novel cyclic GMP stimulated phosphodiesterase from rat brain. Biochem Biophys Res Commun. 1994; 205:1850-1858.
72. Hambleton R, Krall J, Tikishvili E, et al. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem. 2005;280:39168-39174. (Pubitemid 41713868)
73. Degerman E, Belfrage P, Manganiello VC. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem. 1997;272:6823-6826. (Pubitemid 27166373)
74. Huston E, Houslay TM, Baillie GS, et al. cAMP phosphodiesterase-4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signalling. Biochem Soc Trans. 2006;34:504-509. (Pubitemid 44230748)
75. Mongillo M, McSorley T, Evellin S, et al. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res. 2004;95:67-75. (Pubitemid 38931837)
76. Terrin A, Di Benedetto G, Pertegato V, et al. PGE(1) stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: role of compartmentalized phosphodiesterases. J Cell Biol. 2006;175:441-451. (Pubitemid 44708068)
77. Blackman BE, Horner K, Heidmann J, et al. PDE4D and PDE4B function in distinct subcellular compartments in mouse embryonic fibroblasts. J Biol Chem. 2011;286:530-541.
78. Beard MB, Huston E, Campbell L, et al. In addition to the SH3 binding region, multiple regions within the N-terminal noncatalytic portion of the cAMP-specific phosphodiesterase, PDE4A5, contribute to its intracellular targeting. Cell Signal. 2002;14:453-465. (Pubitemid 34214850)
79. 2+-triggered membrane association with selectivity for interaction with phosphatidic acid. J Biol Chem. 2002;277:28298-28309. (Pubitemid 34966785)
80. Beard MB, O'Connell JC, Bolger GB, et al. The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains. FEBS Lett. 1999;460:173-177. (Pubitemid 29479265)
81. McPhee I, Yarwood SJ, Scotland G, et al. Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition. J Biol Chem. 1999;274:11796-11810.
82. O'Connell JC, McCallum JF, McPhee I, et al. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5). Biochem J. 1996;318(pt 1):255-261. (Pubitemid 26283654)
83. Verde I, Pahlke G, Salanova M, et al. Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem. 2001;276:11189-11198. (Pubitemid 38089303)
84. Baillie GS, Sood A, McPhee I, et al. Beta-arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci U S A. 2003;100:940-945. (Pubitemid 36183934)
85. Bolger GB, McCahill A, Huston E, et al. The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins. J Biol Chem. 2003;278: 49230-49238.
86. Yarwood SJ, Steele MR, Scotland G, et al. The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J Biol Chem. 1999;274:14909-14917.
87. Bolger GB, McCahill A, Yarwood SJ, et al. Delineation of RAID1, the RACK1 interaction domain located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5. BMC Biochem. 2002;3:24.
88. Willoughby D, Wong W, Schaack J, et al. An anchored PKA and PDE4 complex regulates subplasmalemmal cAMP dynamics. EMBO J. 2006; 25:2051-2061.
89. Millar JK, Pickard BS, Mackie S, et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science. 2005;310:1187-1191. (Pubitemid 41681745)
90. Asirvatham AL, Galligan SG, Schillace RV, et al. A-kinase anchoring proteins interact with phosphodiesterases in T lymphocyte cell lines. J Immunol. 2004;173:4806-4814. (Pubitemid 39387760)
91. Lee JH, Richter W, Namkung W, et al. Dynamic regulation of cystic fibrosis transmembrane conductance regulator by competitive interactions of molecular adaptors. J Biol Chem. 2007;282:10414-10422. (Pubitemid 47093434)
92. Penmatsa H, Zhang W, Yarlagadda S, et al. Compartmentalized cyclic adenosine 3′,5′-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains. Mol Biol Cell. 2010;21:1097-1110.
93. Pozuelo Rubio M, Campbell DG, Morrice NA, et al. Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. Biochem J. 2005;392:163-172. (Pubitemid 41689412)
94. Puxeddu E, Uhart M, Li CC, et al. Interaction of phosphodiesterase 3A with brefeldin A-inhibited guanine nucleotide-exchange proteins BIG1 and BIG2 and effect on ARF1 activity. Proc Natl Acad Sci U S A. 2009; 106:6158-6163.
95. de Oliveira SK, Hoffmeister M, Gambaryan S, et al. Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. J Biol Chem. 2007;282: 13656-13663. (Pubitemid 47100556)
96. Bolger GB, Peden AH, Steele MR, et al. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem. 2003;278:33351-33363. (Pubitemid 37055787)
97. Vandeput F, Wolda SL, Krall J, et al. Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes. J Biol Chem. 2007;282: 32749-32757. (Pubitemid 350159317)
98. Mongillo M, Tocchetti CG, Terrin A, et al. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res. 2006;98:226-234.
99. Lugnier C, Keravis T, Le Bec A, et al. Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei. Biochim Biophys Acta. 1999;1472:431-446. (Pubitemid 29516631)
100. Senzaki H, Smith CJ, Juang GJ, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J. 2001;15:1718-1726. (Pubitemid 32730219)
101. Michel JJ, Townley IK, Dodge-Kafka KL, et al. Spatial restriction of PDK1 activation cascades by anchoring to mAKAPalpha. Mol Cell. 2005;20:661-672. (Pubitemid 41740689)
102. Kapiloff MS, Jackson N, Airhart N. mAKAP and the ryanodine receptor are part of a multi-component signaling complex on the cardiomyocyte nuclear envelope. J Cell Sci. 2001;114:3167-3176. (Pubitemid 32910471)
103. Ruehr ML, Russell MA, Ferguson DG, et al. Targeting of protein kinase A by muscle A kinase-anchoring protein (mAKAP) regulates phosphorylation and function of the skeletal muscle ryanodine receptor. J Biol Chem. 2003;278:24831-24836. (Pubitemid 37548641)
104. McCartney S, Little BM, Scott JD. Analysis of a novel A-kinase anchoring protein 100 (AKAP 100). Biochem Soc Trans. 1995;23:268S.
105. Bauman AL, Michel JJ, Henson E, et al. The mAKAP signalosome and cardiac myocyte hypertrophy. IUBMB Life. 2007;59:163-169. (Pubitemid 46752479)
106. Pare GC, Easlick JL, Mislow JM, et al. Nesprin-1alpha contributes to the targeting of mAKAP to the cardiac myocyte nuclear envelope. Exp Cell Res. 2005;303:388-399. (Pubitemid 40126271)
107. Dodge KL, Khouangsathiene S, Kapiloff MS, et al. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J. 2001;20:1921-1930. (Pubitemid 32397394)
108. Carlisle Michel JJ, Dodge KL, Wong W, et al. PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex. Biochem J. 2004;381:587-592. (Pubitemid 39120466)
109. Sette C, Conti M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem. 1996;271:16526-16534. (Pubitemid 26239006)
110. Dodge-Kafka KL, Soughayer J, Pare GC, et al. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature. 2005;437:574-578. (Pubitemid 41613557)
111. Hoffmann R, Baillie GS, MacKenzie SJ, et al. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J. 1999;18:893-903. (Pubitemid 29082269)
112. Lehnart SE, Wehrens XH, Reiken S, et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell. 2005;123:25-35. (Pubitemid 41414526)
113. Bers DM. Cardiac ryanodine receptor phosphorylation: target sites and functional consequences. Biochem J. 2006;396:e1-e3.
114. Pare GC, Bauman AL, McHenry M, et al. The mAKAP complex participates in the induction of cardiac myocyte hypertrophy by adrenergic receptor signaling. J Cell Sci. 2005;118:5637-5646. (Pubitemid 43079302)
115. Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun. 2004;322:1178-1191. (Pubitemid 39164648)
116. Lin JW, Wyszynski M, Madhavan R, et al. Yotiao, a novel protein of neuromuscular junction and brain that interacts with specific splice variants of NMDA receptor subunit NR1. J Neurosci. 1998;18:2017-2027. (Pubitemid 28141409)
117. Feliciello A, Cardone L, Garbi C, et al. Yotiao protein, a ligand for the NMDA receptor, binds and targets cAMP-dependent protein kinase II(1). FEBS Lett. 1999;464:174-178. (Pubitemid 30017937)
118. Witczak O, Skalhegg BS, Keryer G, et al. Cloning and characterization of a cDNA encoding an A-kinase anchoring protein located in the centrosome, AKAP450. EMBO J. 1999;18:1858-1868. (Pubitemid 29158529)
119. Kass RS, Wiegers SE. The ionic basis of concentration-related effects of noradrenaline on the action potential of calf cardiac purkinje fibres. J Physiol. 1982;322:541-558. (Pubitemid 12177770)
120. Walsh KB, Kass RS. Regulation of a heart potassium channel by protein kinase A and C. Science. 1988;242:67-69.
121. Sanguinetti MC, Curran ME, Zou A, et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature. 1996;384:80-83. (Pubitemid 26374592)
122. Barhanin J, Lesage F, Guillemare E, et al. K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature. 1996;384:78-80. (Pubitemid 26374591)
123. Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. Physiol Rev. 2005;85:1205-1253. (Pubitemid 41362269)
124. Marx SO, Kurokawa J, Reiken S, et al. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science. 2002;295: 496-499. (Pubitemid 34101639)
125. Fodstad H, Swan H, Laitinen P, et al. Four potassium channel mutations account for 73% of the genetic spectrum underlying long-QT syndrome (LQTS) and provide evidence for a strong founder effect in Finland. Ann Med. 2004;36(suppl 1):53-63. (Pubitemid 38669925)
126. Terrenoire C, Houslay MD, Baillie GS, et al. The cardiac IKs potassium channel macromolecular complex includes the phosphodiesterase PDE4D3. J Biol Chem. 2009;284:9140-9146.
127. Chen L, Kurokawa J, Kass RS. Phosphorylation of the A-kinaseanchoring protein Yotiao contributes to protein kinase A regulation of a heart potassium channel. J Biol Chem. 2005;280:31347-31352. (Pubitemid 41291874)
128. Chen L, Kass RS. Dual roles of the A kinase-anchoring protein Yotiao in the modulation of a cardiac potassium channel: a passive adaptor versus an active regulator. Eur J Cell Biol. 2006;85:623-626. (Pubitemid 43863038)
129. Bajpai M, Fiedler SE, Huang Z, et al. AKAP3 selectively binds PDE4A isoforms in bovine spermatozoa. Biol Reprod. 2006;74:109-118. (Pubitemid 43068797)
130. Tasken KA, Collas P, Kemmner WA, et al. Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area. J Biol Chem. 2001;276:21999-22002.
131. Ahmad F, Lindh R, Tang Y, et al. Differential regulation of adipocyte PDE3B in distinct membrane compartments by insulin and the beta3- adrenergic receptor agonist CL316243: effects of caveolin-1 knockdown on formation/maintenance of macromolecular signalling complexes. Biochem J. 2009;424:399-410.
132. McSorley T, Stefan E, Henn V, et al. Spatial organisation of AKAP18 and PDE4 isoforms in renal collecting duct principal cells. Eur J Cell Biol. 2006;85:673-678. (Pubitemid 43869459)
133. Stefan E, Wiesner B, Baillie GS, et al. Compartmentalization of cAMPdependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. J Am Soc Nephrol. 2007;18:199-212. (Pubitemid 46053433)
134. Lin F, Wang H, Malbon CC. Gravin-mediated formation of signaling complexes in beta 2-adrenergic receptor desensitization and resensitization. J Biol Chem. 2000;275:19025-19034. (Pubitemid 30422869)
135. Deacon SW, Gelfand VI. Of yeast, mice, and men: rab proteins and organelle transport. J Cell Biol. 2001;152:F21-F24.
136. Barnette MS. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog Drug Res. 1999; 53:193-229. (Pubitemid 29515642)
137. Robichaud A, Tattersall FD, Choudhury I, et al. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology. 1999;38:289-297. (Pubitemid 29073550)
138. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468-1475.
139. Amsallem E, Kasparian C, Haddour G, et al. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev. 2005:CD002230.